

Sunday 10 November 2024

10:30–12:00	<b>NEAT ID Symposium: A Focus on Cardiovascular and Metabolic Health and On Late Presenters</b> <i>A workshop organised by the NEAT ID Foundation</i>
<b>Chairs:</b>	<b>Jean-Michel Molina</b> , <i>University of Paris, Paris, France; and Infectious Diseases Department, Saint-Louis and Lariboisière Hospitals, Paris, France</i> <b>Brenda Crabtree-Ramirez</b> , <i>Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico</i>
10:30–10:40	<b>Welcome and introduction. NEAT ID in numbers, background and structure</b> <b>Anton Pozniak</b> , <i>Chelsea and Westminster Hospital, London, UK</i>
10:40–10:59	<b>Cardiovascular metabolic health</b> <b>Esteban Martínez</b> , <i>Infectious Diseases Unit, Hospital Clinic de Barcelona, Barcelona, Spain</i> <b>Laura Waters</b> , <i>Mortimer Market Centre, University College London Hospitals NHS Foundation Trust London, UK</i>
	<b>Two-minutes silence for Armistice Day</b>
11:03–11:20	<b>NEAT ID (study updates, recruitment, grants, project ideas)</b> <b>Jürgen Rockstroh</b> , <i>Department of Medicine I, University Hospital Bonn, Bonn, Germany; and German Centre for Infection Research (DZIF), Bonn, Germany</i>
11:20–11:40	<b>Interactive session on late presenters</b> <b>Casper Rokx</b> , <i>Medical Microbiology &amp; Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands</i> <b>Francois Venter</b> , <i>Ezintsha, University of the Witwatersrand, Johannesburg, South Africa</i>
11:40–11:45	<b>Closing remarks</b> <b>Chairs</b>
11:45–12:00	<b>Thank you to Exec leavers</b> <i>Francois Raffi, Infectious Diseases, University Hospital, Nantes, and Infectious and Tropical Diseases, University of Nantes, Nantes, France</i>
10:30–12:00	<b>STEPS 10: A Community Initiative to Design the Pathway to a Durable ART-Free Control of HIV Infection</b> <i>A workshop by the European AIDS Treatment Group (EATG)</i>
	While stem cell transplants have cured 7 people of HIV, such transplants are dangerous and not easily scaled up. The workshop will discuss the rationale for different approaches to curing HIV. We will hear the perspectives of different people: academic scientists, scientists within the pharmaceutical industry and people living with HIV. There will be time for questions and discussion of key issues.
<b>Chair:</b>	<b>Brian West</b> , <i>Program in Science, EATG, Edinburgh, Scotland, UK</i>
10:30–10:35	Brian West will introduce today's workshop
10:35–10:55	<b>Mark Janse</b> , <i>Erasmus University, Rotterdam, The Netherlands</i> Mark is completing his PhD on HIV cure research in the laboratory of Casper Rokx at Erasmus MC. Mark will summarise different approaches to cure research and provide a rationale for clinical trials he is leading
10:55–11:10*	<b>Memory Sachikonye</b> , <i>UKCAB, London, UK</i> Memory will speak about the potential risks and benefits of analytic treatment interruption (ATI), in particular, its potential impact on the health of women with HIV who may be undergoing menopause, and its impact on cancer survivors

\*There will be a two-minutes silence during this presentation for Armistice Day

Sunday 10 November 2024

10:30–12:00	<b>STEPS 10: A Community Initiative to Design the Pathway to a Durable ART-Free Control of HIV Infection (continued)</b>
11:10–11:25	<b>Jesper D Gunst</b> , Aarhus Universitetshospital, Aarhus, Denmark Jesper will speak about approaches to HIV cure being planned or conducted at his academic centre
11:25–11:40	<b>Arlene Nugent</b> , Global Medical Affairs, AbbVie, Etobicoke, Canada Arlene will present the rationale and some interim data for AbbVie’s approach to obtaining prolonged virological control of ART. She will discuss the need for clinical trials to better understand interim findings
11:40–11:55	<b>Christiaan R de Vries</b> , Clinical Development, Gilead Sciences, New York, NY, USA Christiaan will outline different approaches that Gilead is pursuing in the quest for a cure
11:10–11:25	<b>Wrap Up</b> Brian West
12:00–12:30	Coffee
12:30–13:30	Industry Symposium
13:30–14:15	Lunch, Posters and Exhibition
14:15–15:15	Industry Symposium
15:15–15:30	Coffee
15:30–17:00	Industry Symposium
17:00–17:30	Coffee, Posters and Exhibition
17:30–17:50	<b>Official Opening, Welcome from Glasgow City, and Outcomes, Public Health Responses, Lessons Learned and Current Status of the Glasgow HIV Outbreak (10-year overview)</b>
17:30–17:40	<b>Alexandra Calmy</b> , HIV/AIDS Unit, Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland <b>Chloe Orkin</b> , Blizard Institute, Queen Mary University of London, London, UK; and Barts Health NHS Trust, London, UK
17:40–17:45	<b>Bailie Annette Christie</b> , Glasgow City Council, Glasgow, UK
17:45–17:50	<b>Erica Peters</b> , Infectious Diseases Department, NHS Greater Glasgow and Clyde, Glasgow, UK
17:50–19:00	<b>Stigma in HIV, Past, Present and Future. Stereotyping Patients: Impact on HIV Treatment</b>
17:50–17:55	<b>Welcome and Introduction</b> Chloe Orkin
17:55–18:10	<b>HIV-related stigma and discrimination in the healthcare setting in Europe and Central Asia</b> <b>Teymur Noori</b> , HIV and Migrant Health, European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
18:10–18:25	<b>Rigmor C Berg</b> , Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway
18:25–18:40	<b>The stigma spectrum: Past lessons for future solutions</b> <b>Angelina Namiba</b> , 4M Mentor Mothers Network, London, UK
18:40–19:00	Panel discussion and close
19:00–20:00	Civic Reception hosted by the Lord Provost Jacqueline McLaren and Glasgow City Council

Monday 11 November 2024

08:30–09:45	<b>Experience in the Implementation of Long-Acting Treatment</b> <i>Session in collaboration with the International AIDS Society</i>
Co-chairs:	<b>Simon Collins</b> , <i>HIV i-Base, London, United Kingdom</i> <b>Cissy Kityo</b> , <i>Joint Clinical Research Centre, Kampala, Uganda</i>
08:30–08:35	<b>Welcome and Introduction</b> <b>Cissy Kityo</b>
08:35–08:45	<b>Long-acting treatment for virally suppressed individuals</b> <b>Chloe Orkin</b> , <i>Blizard Institute, Queen Mary University of London, London, UK; and Barts Health NHS Trust, London, UK</i>
08:45–09:00	<b>Long-acting treatment for non-virally suppressed individuals on cabotegravir + rilpivirine: real world evidence</b> <b>Monica Gandhi</b> , <i>Division of HIV, Infectious Diseases, and Global Medicine at University of California San Francisco; and San Francisco General Hospital, San Francisco, CA, USA</i>
09:00–09:10*	<b>O21: Once-weekly islatravir plus lenacapavir in virologically suppressed PWH: Week 48 safety, efficacy, and metabolic changes</b> <b>Amy E Colson</b> , <i>Community Resource Initiative, Boston, MA, USA</i>
09:10–09:20*	<b>O22: Cabotegravir and rilpivirine concentrations and HIV-1 RNA suppression in male and female genital fluids and rectal tissue in people with HIV on antiretroviral therapy with long-acting intramuscular cabotegravir plus rilpivirin</b> <b>Arkaitz Imaz</b> , <i>Infectious Diseases, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain</i>
09:20–09:30*	<b>O23: Efficacy and safety analysis of lenacapavir with broadly neutralising antibodies, teropavimab and zinlirvimab, in people with HIV-1 highly sensitive to one or both broadly neutralising antibodies</b> <b>Paul P Cook</b> , <i>Division of Infectious Diseases and Global Public Health, University of California, San Diego, CA, USA</i>
09:30–09:45	<b>Panel discussion and close</b> <b>All</b>
09:45–10:15	<b>Coffee, Posters and Exhibition</b>
10:15–11:15	<b>Managing Cardiometabolic Risk in HIV: The Role of Old and New Drugs</b>
Co-chairs:	<b>Andrew Carr</b> , <i>Immunology and HIV Unit, St Vincent's Hospital; and University of New South Wales, Sydney, Australia</i> <b>Bernard Surial</b> , <i>Department of Infectious Diseases, University Hospital of Bern, Bern, Switzerland</i>
10:15–10:20	<b>Welcome and Introduction</b> <b>Bernard Surial</b>
10:20–10:33	<b>Managing cardiovascular disease risk in HIV</b> <b>Esteban Martínez</b> , <i>Infectious Diseases Unit, Hospital Clínic de Barcelona, Barcelona, Spain</i>
10:33–10:46	<b>GLP-1 agonists to mitigate cardiometabolic risk (incl role in obesity, diabetes and primary CVD prevention)</b> <b>Christian Delles</b> , <i>School of Cardiovascular &amp; Metabolic Health, University of Glasgow, Glasgow, UK</i>

\*Oral presentation from submitted abstract

Monday 11 November 2024

10:15–11:15	<b>Managing Cardiometabolic Risk in HIV: The Role of Old and New Drugs (continued)</b>
10:46–10:59	<b>Managing ART-associated weight gain in HIV</b> <i>Cristina Mussini, Department of Infectious Diseases and Tropical Medicine, University Hospital, Modena, Italy</i>
10:59–11:15	<b>Panel discussion and close</b> <i>All, joined by Nadine Jaschinski, The International Cohort Consortium of Infectious Disease (RESPOND), and CHIP, Rigshospitalet, Copenhagen, Denmark</i>
11:15–12:30	<b>Elimination of HIV Vertical Transmission Across the World</b> <i>In collaboration with the Euroguidelines in Central and Eastern Europe (ECEE) Network Group</i>
<b>Co-chairs:</b>	<b>Linda-Gail Bekker, Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa</b> <b>Cristiana Oprea, Carol Davila University of Medicine and Pharmacy, Bucharest, and Infectious Diseases and HIV Department, Victor Babes Hospital for infectious and Tropical Diseases, Bucharest, Romania</b>
11:15–11:25	<b>Welcome and introduction</b> <b>Cristiana Oprea</b>
11:25–11:35	<b>Antiretrovirals in pregnancy and breastfeeding: a research toolkit</b> <i>Shahin Lockman, Brigham and Women’s Hospital and Harvard TH Chan School of Public Health, Boston, MA, USA; and Botswana Harvard Health Partnership, Gaborone, Botswana</i>
11:35–11:47	<b>Human rights and elimination of HIV vertical transmission, including co-infection – insights from Eastern Europe and Central Asia</b> <i>Justyna Kowalska, Department of Adult Infection Diseases, Medical University of Warsaw, Warsaw, Poland; and HIV Out-Patient Clinic, Hospital for Infectious Diseases, Warsaw, Poland</i>
11:47–11:59	<b>Sexual violence, HIV and pregnancy outcomes in South America</b> <b>Claudia Cortes, Faculty of Medicine, University of Chile, Santiago, Chile</b>
11:59–12:11	<b>Early infant diagnosis and linkage to HIV care for children – are we there yet?</b> <i>Oxana Turcanu, Perinatal Center, Clinical Municipal Hospital "Gheorghe Paladi", Chişinău, Moldova</i>
12:11–12:30	<b>Panel discussion and close</b> <b>All</b>
12:30–13:45	<b>Lunch, Posters and Exhibition</b>
12:45–13:45	<b>Industry Symposium</b>
13:45–14:30	<b>Antiretroviral Treatment Strategies</b>
<b>Co-chairs:</b>	<b>Magdalena Ankiersztejn-Bartczak, Foundation for Social Education, Warsaw, Poland</b> <b>Alexandra Calmy, HIV/AIDS Unit, Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland</b>
13:45–13:50	<b>Welcome and introduction</b> <b>Alexandra Calmy</b>
13:50–14:10	<b>New treatments and future combinations</b> <i>Jose Arribas, Infectious Diseases Unit, La Paz Hospital, Madrid, Spain; and School of Medicine, Autonoma University School of Medicine, Madrid, Spain</i>

Monday 11 November 2024

13:45–14:30	Antiretroviral Treatment Strategies (continued)
14:10–14:20*	<b>O24: Comparable efficacy and safety of dolutegravir/lamivudine to a three-drug regimen amongst ARV naive people living with HIV with CD4 &lt;200/mm<sup>3</sup>: the DOLCE study</b> <i>Pedro Cahn, Research Department, Fundacion Huesped, Buenos Aires, Argentina</i>
14:20–14:30	Panel discussion and close All
14:30–15:45	Infection Prevention
Co-chairs:	<i>Iskandar Azwa, University Malaya, Kuala Lumpur, Malaysia</i> <i>Georg Behrens, Hannover Medical School, Hannover, Germany</i>
14:30–14:35	Welcome and Introduction Iskandar Azwa
14:35–14:45	<b>A provider’s perspective of doxyPEP</b> <i>Jade Ghosn, Department of Infectious Diseases, Bichat University Hospital, Paris, France</i>
14:45–14:55	<b>A doxyPEP perspective from the community</b> <i>Sophie Strachan, The Sophia Forum, London, UK; and Chelsea and Westminster Hospital NHS Foundation Trust, London, UK</i>
14:55–15:05*	<b>O25: Post-exposure prophylaxis with doxycycline (doxyPEP) in a cohort of men who have sex with men (MSM) in high risk for sexually transmitted infections (STI). The PRIDOX study</b> <i>Rosario Palacios, Hospital Universitario Virgen de la Victoria, Infectious Diseases Unit, IBIMA, Málaga, Spain</i>
15:05–15:20	<b>Mpox: 2024 update</b> <i>Dimie Ogoina, Bayelsa Medical University, Yenagoa, Nigeria</i>
15:20–15:30*	<b>O26: Both smallpox MVA vaccine and mpox infection produce potent immune response to mpox in people living with HIV</b> <i>Maryam Khan, SHARE Collaborative, Immunobiology, Blizard Institute, Queen Mary University of London, London, UK</i>
15:30–15:45	Panel discussion and close All
15:45–17:00	Supporting an Older Population of People Living With HIV, or at Risk of HIV <i>In collaboration with the British HIV Association</i>
Co-chairs:	<i>Giovanni Guaraldi, Modena HIV Metabolic Clinic, University of Modena and Reggio Emilia, Modena, Italy</i> <i>Nicoletta Policek, UK Community Advisory Board (UK-CAB), UK, and European AIDS Treatment Group, Brussels, Belgium</i>
15:45–15:50	Welcome and Introduction Giovanni Guaraldi
15:50–16:00	<b>Global perspectives on HIV in older people</b> <i>Caroline Sabin, Institute for Global Health, University College London (UCL), London, UK</i>

\*Oral presentation from submitted abstract

**Monday 11 November 2024**

<b>15:45–17:00</b>	<b>Supporting an Older Population of People Living With HIV, or at Risk of HIV (continued)</b> <i>In collaboration with the British HIV Association</i>
<b>16:00–16:10</b>	<b>Models of care for older people with HIV</b> <i>Tristan Barber, Ian Charleson Day Centre, Royal Free Hospital, London, UK</i>
<b>16:10–16:20</b>	<b>Are we adequately supporting women ageing with HIV?</b> <i>Yvonne Gilleece, Claude Nicol Centre (Sexual Health) and Lawson Unit (HIV), Brighton and Sussex University Hospitals NHS Trust, Brighton, UK</i>
<b>16:20–16:30</b>	<b>Supporting older populations of Black heritage living with or at risk of HIV</b> <i>Juddy Otti-Olunga, HIV Services, Africa Advocacy Foundation, and The Sophia Forum, London, UK</i>
<b>16:30–16:40</b>	<b>Adults with perinatally acquired HIV: emerging clinical outcomes and data gaps</b> <i>Merle Henderson, Clinical Trials Centre, Imperial College Healthcare NHS Trust, London, UK</i>
<b>16:40–17:00</b>	<b>Panel discussion and close</b> <b>All</b> , led by <b>Nicoletta Policek</b>
<b>17:00–17:30</b>	<b>Coffee, Posters and Exhibition</b>
<b>17:30–19:00</b>	<b>Industry Symposium</b>

Tuesday 12 November 2024

08:30–09:30	<b>Industry Symposium</b>
09:30–09:45	Coffee, Posters and Exhibition
09:45–11:10	<b>Integrase Strand Transfer Inhibitor (INSTI) Resistance</b>
<b>Co-chairs:</b>	<b>Anton Pozniak</b> , <i>Chelsea and Westminster Hospital, London, UK</i> <b>Marco Vitoria</b> , <i>Department of HIV/AIDS, World Health Organization, Geneva, Switzerland</i>
09:45–09:50	Welcome and introduction Anton Pozniak
09:50–10:05	INSTI resistance global data trends Daniel Kuritzkes, <i>Division of Infectious Diseases, Brigham and Women’s Hospital, Boston, MA, USA</i>
10:05–10:20	2 <sup>nd</sup> generation INSTI resistance in randomized trials and cohorts Andrew Hill, <i>Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK</i>
10:20–10:35	HIV drug resistance testing: new strategies and the promise of new technologies Gert Van Zyl, <i>Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa</i>
10:35–10:45*	<b>O31: Clinical features and resistance patterns during second-generation INSTI failure: the ROSETTA-registry</b> Mafalda NS Miranda, <i>Translational Virology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, Netherlands</i>
10:45–10:55*	<b>O32: Virological outcomes and associated factors among treatment-naive patients with HIV-1 on dolutegravir based regimen in a programmatic setting in Thailand</b> Napon Hiranburana, <i>HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thai Red Cross AIDS Research Centre, Hiranburana, Bangkok, Thailand</i>
10:55–11:10	Panel discussion and close All, Led by <b>Marco Vitoria</b> , <i>Department of HIV/AIDS, World Health Organization, Geneva, Switzerland</i>
11:10–11:40	<b>HIV in migrant populations</b> <i>The Lancet HIV</i>
	<i>A ‘fireside chat’ between the session moderator and invited guests to learn more about The Lancet HIV’s upcoming paper series. The ‘chat’ will discuss how the concept came about, and explore the challenges faced along the way as the development of the series progressed.</i>
<b>Moderator:</b>	<b>Peter Hayward</b> , <i>The Lancet HIV, Lancet Group, London, UK</i>
<b>Guests:</b>	<b>Claudia Cortes</b> , <i>Faculty of Medicine, University of Chile, Santiago, Chile</i> <b>Alena Kamenshchikova</b> , <i>Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands</i>

\*Oral presentation from submitted abstract

Tuesday 12 November 2024

<b>11:40–13:00</b>	<b>Clinical Case Study Session</b> <i>In collaboration with the Liverpool DDI team</i>
<b>Facilitators:</b>	<b>Roy Gulick</b> , <i>Department of Medicine, Weill Cornell Medicine, New York, NY, USA</i> <b>Saye Khoo</b> , <i>Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK; and Royal Liverpool University Hospital, Liverpool, UK</i> <b>Catia Marzolini</b> , <i>Department of Infectious Diseases &amp; Hospital Epidemiology, University Hospital of Basel, Basel, Switzerland; and Service of Clinical Pharmacology, Lausanne University Hospital, Lausanne, Switzerland; and School of Molecular &amp; Clinical Pharmacology, University of Liverpool, Liverpool, UK</i>
<b>Panellists:</b>	<b>Marta Boffito</b> , <i>Clinical Research Facility / HIV Service, Chelsea and Westminster Hospital, London, UK; and Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK</i> <b>Lene Ryom</b> , <i>Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark</i> <b>Claudia Cortes</b> , <i>Faculty of Medicine, University of Chile, Santiago, Chile</i> <b>Karine Lacombe</b> , <i>Department of Infectious Diseases, Hospital Saint Antoine, Paris, France</i>
<b>11:40–11:50</b>	<b>Celebrating 25 years of the work of the Liverpool DDI Team</b> <b>Saye Khoo</b>
<b>11:50–12:15</b>	<b>Case 1: Seroconversion on long-acting PrEP</b> <b>Jean-Michel Molina</b> , <i>University of Paris, Paris, France; and Infectious Diseases Department, Saint-Louis and Lariboisière Hospitals, Paris, France</i>
<b>12:15–12:35</b>	<b>Case 2: Low CV risk – statins case</b> <b>Laura Waters</b> , <i>Mortimer Market Centre, University College London Hospitals NHS Foundation Trust, London, UK</i>
<b>12:35–12:55</b>	<b>Case 3: TB with ART?</b> <b>Catherine Orrell</b> , <i>Antiretroviral Treatment Division (ART), Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa</i>
<b>12:55–13:00</b>	<b>Close</b> <b>Saye Khoo</b>
<b>13:00–14:15</b>	<b>Lunch, Posters and Exhibition</b>
<b>13:15–14:15</b>	<b>Industry Symposium</b>
<b>14:15–15:15</b>	<b>HIV Cure: Where Are We Now?</b>
<b>Co-chairs:</b>	<b>Peter Reiss</b> , <i>Amsterdam UMC, University of Amsterdam in Amsterdam, The Netherlands</i> <b>Alain Volny-Anne</b> , <i>Paris, France</i>
<b>14:15–14:20</b>	<b>Welcome and introduction to this year’s Joep Lange and Jacqueline van Tongeren key note lecture, dedicated to them in recognition of their commitment and passion to rid the world of HIV/AIDS</b> <b>Peter Reiss</b>
<b>14:20–14:45</b>	<b>Keynote Lecture – HIV cure: Lessons learnt and prospects for the future</b> <b>Linos Vandekerckhove</b> , <i>Department of Internal Medicine and Pediatrics, HIV Cure Research Center, University Hospital Ghent, Ghent University, Ghent, Belgium</i>



Tuesday 12 November 2024

14:15-15:15	<b>HIV Cure: Where Are We Now? (continued)</b>
14:45-15:00	<b>Ethics in trials of HIV cure</b> <i>Karine Dubé, School of Medicine and Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA</i>
15:00-15:15	<b>Panel discussion</b> <i>All joined by Sarah Fidler, Imperial College NHS Trust, and Imperial College London, London, UK</i>
15:15-16:00	<b>Keynote Lecture: Artificial Intelligence and Digital Technologies: Their Role in Future HIV Research, Treatment and Care</b>
<b>Chair:</b>	<b>Peter Hunt, University of California, San Francisco, United States</b>
	<b>Alastair C Van Heerden, Center for Community Based Research, Human Sciences Research Council, Pietermaritzburg, South Africa; and SAMRC/Wits Developmental Pathways for Health Research Unit, University of the Witwatersrand, Johannesburg, South Africa</b>
16:00-17:00	<b>Emerging Ethical and Participation Challenges in HIV Research and Development</b> <i>In collaboration with the European AIDS Treatment Group (EATG)</i>
<b>Co-chairs:</b>	<b>Mario Cascio, European AIDS Treatment Group, Palermo, Italy</b> <b>Nicoletta Policek, UK Community Advisory Board (UK-CAB), UK, and European AIDS Treatment Group, Belgium</b>
16:00-16:05	<b>Welcome and Introduction</b> <b>Nicoletta Policek</b>
16:05-16:15	<b>The challenges of ATI in HIV cure research from the community perspective</b> <i>Gus Cairns, London, UK</i>
16:15-16:25	<b>Engagement with the community</b> <i>Grzegorz Jezierski, Lambda Warszawa, Warsaw, Poland</i>
16:25-16:35	<b>Bridging the gap: Ensuring gender equity in clinical trials for better health outcomes</b> <i>Oana Sandulescu, Infectious Diseases, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania</i>
16:35-16:45	<b>Broadening horizons: Enhancing transgender inclusion and global diversity in clinical trials</b> <i>Amanita Calderon Cifuentes, Transgender Europe, Berlin, Germany</i>
16:45-17:00	<b>Discussion, Q&amp;A and conclusions</b> <b>All</b>
17:00-17:30	<b>Coffee, Posters and Exhibition</b>
17:30-19:00	<b>Industry Symposium</b>

Wednesday 13 November 2024

08:30–09:45	<b>Guidelines Session: 2024 Update and CV Risk Recommendations</b> <i>In collaboration with the European AIDS Clinical Society (EACS)</i>
<b>Co-chairs:</b>	<b>Juan Ambrosioni</b> , <i>HIV/AIDS Unit and Infectious Disease Service, Hospital Clinic-IDIBAPS, University of Barcelona, Barcelona, Spain</i> <b>Jürgen Rockstroh</b> , <i>Department of Medicine I, University Hospital Bonn, Bonn, Germany; and German Centre for Infection Research (DZIF), Bonn, Germany</i>
08:30–08:35	<b>Welcome and introduction, and the 2024 EACS guidelines: new format, new content and new terms of reference</b> <b>Juan Ambrosioni</b>
08:35–08:45	<b>Update on ART for treatment and prevention</b> <b>Laura Levi</b> , <i>Department of Infectious Diseases, St-Louis and Lariboisière Hospitals, APHP, University of Paris Cité, Paris, France</i>
08:45–08:55	<b>Update on co-infections, sexually transmitted infections and opportunistic infections</b> <b>Andrea Mastrangelo</b> , <i>Department of Allergy and Clinical Immunology, Centre Hospitalier Universitaire Vaudoise (CHUV), Lausanne, Switzerland</i>
08:55–09:05	<b>Update on paediatric HIV management, vertical transmission and infant feeding</b> <b>Steven Welch</b> , <i>Department of Paediatrics, Heartlands Hospital, University Hospitals Birmingham, Birmingham, UK</i>
09:05–09:25	<b>Co-morbidities: update on cardiovascular and metabolic risk, including statins recommendations and other co-morbidities</b> <b>Jasmini Alagaratnam</b> , <i>Department of Sexual Health &amp; HIV, Chelsea &amp; Westminster Hospital NHS Foundation Trust, London, UK; and Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, UK</i>
09:25–09:45	<b>Panel discussion and closing remarks</b> <b>Esteban Martínez</b> , <i>Infectious Diseases Unit, Hospital Clínic de Barcelona, Barcelona, Spain</i> <b>Catia Marzolini</b> , <i>Department of Infectious Diseases &amp; Hospital Epidemiology, University Hospital of Basel, Basel, Switzerland; and Service of Clinical Pharmacology, Lausanne University Hospital, Lausanne, Switzerland; and School of Molecular &amp; Clinical Pharmacology, University of Liverpool, Liverpool, UK</i> <b>Luís Mendão</b> , <i>GAT – Portuguese Activist Group on Treatments, Lisbon, Portugal</i> <b>Cristiana Oprea</b> , <i>Carol Davila University of Medicine and Pharmacy, Bucharest, and Infectious Diseases and HIV Department, Victor Babes Hospital for infectious and Tropical Diseases, Bucharest, Romania</i> <b>Steven Welch</b>
09:45–10:15	<b>Coffee, Posters and Exhibition</b>
10:15–11:45	<b>Co-morbidities and Co-infections</b>
<b>Co-chairs:</b>	<b>Maxime Hentzien</b> , <i>Infectious Diseases, University of Reims, Champagne-Ardenne, France</i> <b>Milosz Parczewski</b> , <i>Pomeranian Medical University, Szczecin, Poland</i>
10:15–10:30*	<b>O41: Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the National Prospective Real-World ONCOVIHAC ANRS CO24 cohort study</b> <b>Jean-Philippe Spano</b> , <i>Institut Pierre Louis d'Epidémiologie et de Santé Publique, INSERM, Sorbonne Université, and Département d'Oncologie Médicale, Hôpital Pitié-Salpêtrière, Paris, France</i>

\*Oral presentation from submitted abstract

Wednesday 13 November 2024

10:15–11:45	<b>Co-morbidities and Co-infections (continued)</b>
10:30–10:45*	<b>O42: Depression and anxiety symptoms among people with HIV in the UK: prevalence, correlates and treatment. Results from the Positive Voices 2022 study</b> Fiona Lampe, <i>Institute for Global Health, University College London, London, UK</i>
10:45–11:00*	<b>O43: Randomised, multicentre, double-blind clinical trial designed to evaluate the safety and convenience of switching from dolutegravir/lamivudine to bicitgravir/emtricitabine/ tenofovir alafenamide in people with HIV, good virological control and neuropsychiatric comorbidities: week 24 results from the GESIDA 11920 - MIND study</b> Ignacio Perez Valero, <i>Hospital Universitario Reina Sofia, IMIBIC, CIBERINFEC, Enfermedades Infecciosas, Cordoba, Spain</i>
11:00–11:15*	<b>O44: A phase 3 randomised study to evaluate the safety, tolerability and immunogenicity of V116, an adult-specific pneumococcal conjugate vaccine (PCV), followed by PCV15, in adults living with HIV (STRIDE-7)</b> Heather Platt, <i>Global Clinical Development, Vaccines, Merck Research Laboratories, Merck &amp; Co., Rahway, NJ, USA<sup>†</sup></i>
11:15–11:30*	<b>O45: Prevalence trends of active HCV infection among people with HIV in Spain (2002-2023): nearing elimination</b> Juan Berenguer, <i>Infectious Diseases, Hospital Gregorio Marañón, IISGM, CIBERINFEC, Madrid, Spain</i>
11:30–11:45*	<b>O46A: Long-term outcomes following liver transplantation (LT) in patients with HIV (PWH): a retrospective single-centre case-control study</b> and <b>O46B: HIV-positive donor to positive recipient kidney transplantation: a nationwide survey</b> Jose M Miro, <i>Infectious Diseases Service - HIV/AIDS Unit, Hospital Clinic-Institut D'investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain</i>
11:45–12:50	<b>PrEP-ing for the Future</b>
<b>Co-chairs:</b>	<b>Alexandra Calmy</b> , <i>HIV/AIDS Unit, Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland</i> <b>Chloe Orkin</b> , <i>Blizard Institute, Queen Mary University of London, London, UK; and Barts Health NHS Trust, London, UK</i>
11:45–12:05	<b>Keynote Lecture: PrEP Therapeutic Agents - What's on the Horizon and Access?</b> <i>Lock Lecture gifted by the Royal College of Physicians and Surgeons of Glasgow</i> Linda-Gail Bekker, <i>Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa</i>
12:05–12:15*	<b>O47: Differences in oral PrEP use patterns and intention to use long-acting regimens among MSM between formal and informal PrEP provision pathways in 20 European countries: a latent class analysis</b> Haoyi Wang, <i>Department of Work and Social Psychology, Maastricht University, Maastricht, The Netherlands</i>
12:15–12:25*	<b>O48: Persistence in use of twice-yearly lenacapavir versus daily oral PrEP in the PURPOSE 1 Phase 3 trial</b> Linda-Gail Bekker

\*Oral presentation from submitted abstract

## Wednesday 13 November 2024

11:45–12:50	PrEP-ing for the Future (continued)
12:25–12:35*	<b>O49: Twice-yearly lenacapavir PrEP in cisgender gay men, transgender women and men, and gender-diverse people (PURPOSE 2)</b> <b>Onyema Ogbuagu</b> , <i>Department of Infectious Diseases and Pharmacology, Yale School of Medicine, New Haven, CT, USA</i>
12:35–12:50	Panel discussion All
12:50–13:00	Congress close
12:35–12:50	Alexandra Calmy and Chloe Orkin
13:00–13:45	Lunch, Posters and Departures

Oral Abstracts

Monday 11 November 2024

**O21: Once-weekly islatravir plus lenacapavir in virologically suppressed PWH: week 48 safety, efficacy, and metabolic changes**

**Amy E Colson**<sup>1</sup>, Gordon E Crofoot<sup>2</sup>, Peter J Ruane<sup>3</sup>, Moti N Ramgopal<sup>4</sup>, Alexandra W Dretler<sup>5</sup>, Ronald G Nahass<sup>6</sup>, Gary I Sinclair<sup>7</sup>, Mezgebe Berhe<sup>8</sup>, Fadi Shihadeh<sup>9</sup>, Shan-Yu Liu<sup>9</sup>, Stephanie Klopfer<sup>10</sup>, Sharline Madera<sup>9</sup>, Hadas Dvory-Sobol<sup>9</sup>, Martin S Rhee<sup>9</sup>, Elizabeth G Rhee<sup>10</sup>, Jared Baeten<sup>9</sup>, Joseph Eron<sup>11</sup>

<sup>1</sup>Community Resource Initiative, Boston, MA, USA. <sup>2</sup>The Crofoot Research Center, Houston, TX, USA. <sup>3</sup>Ruane Clinical Research, Los Angeles, CA, USA. <sup>4</sup>Midway Immunology & Research Center, Fort Pierce, FL, USA. <sup>5</sup>Metro Infectious Disease Consultants, Decatur, GA, USA. <sup>6</sup>ID Care, Hillsborough, NJ, USA. <sup>7</sup>Prism Health North Texas, Dallas, TX, USA. <sup>8</sup>North Texas Infectious Diseases Consultants, Dallas, TX, USA. <sup>9</sup>Gilead Sciences, Foster City, CA, USA. <sup>10</sup>Merck & Co., Inc., Rahway, NJ, USA. <sup>11</sup>University of North Carolina, Chapel Hill, NC, USA

**O22: Cabotegravir and rilpivirine concentrations and HIV-1 RNA suppression in male and female genital fluids and rectal tissue in people with HIV on antiretroviral therapy with long-acting intramuscular cabotegravir plus rilpivirine**

Analuz Fernandez<sup>1</sup>, Sofia Scévola<sup>1</sup>, Jordi Niubó<sup>1</sup>, Craig Sykes<sup>2</sup>, Amanda P Schauer<sup>2</sup>, Camila Piatti<sup>1</sup>, Sandra Morenilla<sup>1</sup>, Alicia Sedó<sup>1</sup>, Irene Soriano<sup>1</sup>, Benito Garcia<sup>1</sup>, Daniel Medina<sup>1</sup>, Juan Tiraboschi<sup>1</sup>, Maria Saumoy<sup>1</sup>, Mackenzie L Cottrell<sup>2</sup>, **Arkaitz Imaz**<sup>1</sup>

<sup>1</sup>Bellvitge University Hospital, Infectious Diseases, L'Hospitalet de Llobregat, Barcelona, Spain. <sup>2</sup>University of North Carolina at Chapel Hill, Eshelman School of Pharmacy, Chapel Hill, NC, USA

**O23: Efficacy and safety analysis of lenacapavir with broadly neutralising antibodies, teropavimab and zinlirvimab, in people with HIV-1 highly sensitive to one or both broadly neutralising antibodies**

Susan J Little<sup>1</sup>, **Paul P Cook**<sup>2</sup>, Kwad Mponponsuo<sup>3</sup>, Edwin DeJesus<sup>4</sup>, Gordon E Crofoot<sup>5</sup>, Hailin Huang<sup>6</sup>, Linda Gorgos<sup>7</sup>, Sean E Collins<sup>3</sup>, Joseph J Eron<sup>8</sup>

<sup>1</sup>University of California, Division of Infectious Diseases, San Diego, CA, USA. <sup>2</sup>East Carolina University, Division of Infectious Diseases, Greenville, NC, USA. <sup>3</sup>Gilead Sciences, Inc., Clinical Development, Foster City, CA, USA. <sup>4</sup>Orlando Immunology Center, Infectious Diseases, Orlando, FL, USA. <sup>5</sup>The Crofoot Research Center, Infectious Diseases, Houston, TX, USA. <sup>6</sup>Gilead Sciences, Inc., Biostatistics, Foster City, CA, USA. <sup>7</sup>AXCES Research Group, Infectious Diseases, Santa Fe, NM, USA. <sup>8</sup>University of North Carolina, Infectious Diseases, Chapel Hill, NC, USA

**O24: Comparable efficacy and safety of dolutegravir/lamivudine to a three-drug regimen amongst ARV naive people living with HIV with CD4 <200/mm3: the DOLCE study**

Maria Ines Figueroa<sup>1</sup>, Carlos Brites<sup>2</sup>, Diego Cecchini<sup>3</sup>, Aline Santos Ramalho Teixeira Benvenuto<sup>4</sup>, Jose Luis Francos<sup>5</sup>, Marcus Lacerda<sup>6</sup>, Maria Jose Rolon<sup>7</sup>, Jose Valdez Madruga<sup>8</sup>, Eduardo Sprinz<sup>9</sup>, Tamara Newman Lobato Souza<sup>10</sup>, Pablo Parenti<sup>11</sup>, Demetrius Montenegro<sup>12</sup>, Daniela Converso<sup>1</sup>, Gissella Mernies<sup>1</sup>, Omar Sued<sup>13</sup>, **Pedro Cahn**<sup>1</sup>

<sup>1</sup>Fundacion Huesped, Research Department, Buenos Aires, Argentina. <sup>2</sup>Fundacao Bahiana de Infectologia, Salvador, Brazil. <sup>3</sup>Hospital General de Agudos Dr Cosme Argerich, Buenos Aires, Argentina. <sup>4</sup>Hospital Geral de Nova Iguacu, Nova Iguacu, Brazil. <sup>5</sup>Hospital de Infecciosas Francisco J. Muñiz, Buenos Aires, Argentina. <sup>6</sup>Fundacao de Medicina Tropical de Amazonas - FMT/IMT/AM, Manaus, Brazil. <sup>7</sup>Hospital General de Agudos Juan A Fernandez, Buenos Aires, Argentina. <sup>8</sup>Centro de Treinamiento e Referencia DST/AIDS, Sao Paulo, Brazil. <sup>9</sup>Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil. <sup>10</sup>Centro de Pesquisa Instituto de Infectologia Emilio Ribas, Sao Paulo, Brazil. <sup>11</sup>Instituto CAICI, Rosario, Argentina. <sup>12</sup>Universidade de Pernambuco, Hospital Universitario Oswaldo Cruz, Recife, Brazil. <sup>13</sup>Panamerican Health Organization, Washington, DC, USA

**O25: Post-exposure prophylaxis with doxycycline (DoxyPEP) in a cohort of men who have sex with men (MSM) in high risk for sexually transmitted infections (STI): the PRIDOX study**

**Rosario Palacios**<sup>1</sup>, Cristina Gómez-Ayerbe<sup>1</sup>, María López-Jodar<sup>1</sup>, Salvador Martín-Cortés<sup>1</sup>, Isabel Ascensión Pérez-Hernández<sup>1</sup>, Andrea Prolo<sup>1</sup>, Marina Villalobos<sup>1</sup>, Victoria García-López<sup>2</sup>, Jesús Santos<sup>1</sup>

<sup>1</sup>Hospital Universitario Virgen de la Victoria, Infectious Diseases Unit, Málaga, Spain. <sup>2</sup>Hospital Universitario Virgen de la Victoria, Microbiology Department, Málaga, Spain

Oral Abstracts (continued)

Monday 11 November 2024 (continued)

**O26: Both smallpox MVA vaccine and mpox infection produce potent immune response to mpox in people living with HIV**

Maryam Khan<sup>1</sup>, Scott Jones<sup>2</sup>, Hafiza Rahman<sup>3</sup>, Helena Miras<sup>3</sup>, John Thornhill<sup>4</sup>, Ashley Otter<sup>2</sup>, Chloe Orkin<sup>4</sup>

<sup>1</sup>SHARE Collaborative, Immunobiology, Blizard Institute, Queen Mary University of London, London, UK. <sup>2</sup>UK Health Security Agency, Emerging Pathogen Serology, London, UK. <sup>3</sup>Barts Health NHS Trust, Grahame Hayton Unit, London, UK. <sup>4</sup>Immunobiology, Blizard Institute, Queen Mary University of London, London, UK

Tuesday 12 November 2024

**O31: Clinical features and resistance patterns during second-generation INSTI failure: the ROSETTA-registry**

Mafalda N S Miranda<sup>1</sup>, Carole Seguin-Devaux<sup>2</sup>, Ana B Abecasis<sup>3</sup>, Fatima Bikhezar<sup>1</sup>, Ricardo Diaz<sup>4</sup>, Joseph Fokam<sup>5</sup>, Laurence Guilorit<sup>2</sup>, Thibault Mesplede<sup>6</sup>, Suzanne McCluskey<sup>7</sup>, Monique Nijhuis<sup>1</sup>, Dimitrios Paraskevis<sup>8</sup>, Karol Serwin<sup>9</sup>, Annelies Verbon<sup>10</sup>, Berend van Welzen<sup>10</sup>, Ferdinand Wit<sup>11</sup>, Ivailo Alexiev<sup>12</sup>, Josip Begovac<sup>13</sup>, Michael Böhm<sup>14</sup>, Federico Garcia<sup>15</sup>, Perpétua Gomes<sup>16</sup>, Itzchak Levi<sup>17</sup>, Rolf Kaiser<sup>14</sup>, Josep M Llibre<sup>18</sup>, Kaja Mielczak<sup>9</sup>, Orna Mor<sup>19</sup>, Milosz Parczewski<sup>9</sup>, Murat Sayan<sup>20</sup>, Alessandra Simões Bassini<sup>4</sup>, Karolien Stoffels<sup>21</sup>, Margarida Veloso<sup>22</sup>, Jeroen van Kampen<sup>6</sup>, Annemarie M J Wensing<sup>23</sup>

<sup>1</sup>University Medical Center Utrecht, Translational Virology, Department of Medical Microbiology, Utrecht, Netherlands. <sup>2</sup>Luxembourg Institute of Health, Infection and Immunotherapy Research Group, Department of Infection and Immunity, Alzette, Luxembourg. <sup>3</sup>Institute of Hygiene and Tropical Medicine, New University of Lisbon (IHMT/UNL), Global Health and Tropical Medicine (GHTM), Associate Laboratory in Translation and Innovation towards Global Health (LA-REAL), Lisbon, Portugal. <sup>4</sup>University Federal de São Paulo, São Paulo, Brazil. <sup>5</sup>Chantal Biya International Reference Centre for Research on the Prevention and Management of HIV/AIDS (CIRCB), Virology Laboratory, Yaoundé, Cameroon. <sup>6</sup>Erasmus University Medical Center, Rotterdam, Netherlands. <sup>7</sup>Harvard Medical School, Massachusetts General Hospital, Division of Infectious Diseases, Boston, MA, USA. <sup>8</sup>Medical School of the National and Kapodistrian University of Athens, -, Athens, Greece. <sup>9</sup>Pomeranian Medical University, Szczecin, Poland. <sup>10</sup>University Medical Center Utrecht, Department of Infectious Diseases, Utrecht, Netherlands. <sup>11</sup>Stichting HIV Monitoring, Amsterdam, Netherlands. <sup>12</sup>National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria. <sup>13</sup>University Hospital for Infectious Diseases, Zagreb, Croatia. <sup>14</sup>University Hospital of Cologne, University of Cologne, Institute of Virology, Cologne, Germany. <sup>15</sup>University Hospital San Cecilio, Granada, Spain. <sup>16</sup>Egas Moniz School of Health & Science, Egas Moniz Center for Interdisciplinary Research (CiiEM), Caparica, Portugal. <sup>17</sup>Ministry of Health & Sheba Medical Center, Tel-Aviv, Israel. <sup>18</sup>University Hospital Germans Trias, Badalona, Spain. <sup>19</sup>Ministry of Health and School of Medicine, Tel Aviv University, Central Virology Laboratory, Tel Aviv, Israel. <sup>20</sup>Kocaeli University, Clinical Laboratory, PCR Unit, Kocaeli, Turkey. <sup>21</sup>CHU Saint-Pierre, UMC Sint-Pieter, Brussels, Belgium. <sup>22</sup>Laboratório de Biologia Molecular (LMCBM, SPC, ULSLO-HEM), Lisbon, Portugal. <sup>23</sup>University Medical Center Utrecht, Translational Virology, Department of Global Public Health & Bioethics, Julius Center for Health Sciences and Primary Care, Utrecht, Netherlands

**O32: Virological outcomes and associated factors among treatment-naive patients with HIV-1 on dolutegravir based regimen in a programmatic setting in Thailand**

Napon Hiranburana<sup>1</sup>, Opass Putcharoen<sup>2</sup>, Cheewanan Lertpiriyasuwat<sup>3</sup>, Sairat Noknoi<sup>4</sup>, Jiratchaya Sophonphan<sup>5</sup>, Supunnee Jirajariyave<sup>6</sup>, Stephen J Kerr<sup>7</sup>, Ploenchan Chetchotisakd<sup>8</sup>, Chureeratana Bowonwatanuwong<sup>9</sup>, Kiat Ruxrungham<sup>9</sup>, Anchalee Avihingsanon<sup>5</sup>

<sup>1</sup>Thai Red Cross AIDS Research Centre, HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok, Thailand. <sup>2</sup>Medicine Faculty, Chulalongkorn University, Infectious Disease, Bangkok, Thailand. <sup>3</sup>Division of AIDS and STI, Department of Disease Control, Ministry of Public Health, Disease Control, Bangkok, Thailand. <sup>4</sup>HIV-NAT, Thai Red Cross AIDS Research Center, Research, Bangkok, Thailand. <sup>5</sup>HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thai Red Cross AIDS Research Centre, Research, Bangkok, Thailand. <sup>6</sup>Taksin Hospital, Internal Medicine, Bangkok, Thailand. <sup>7</sup>Faculty of Medicine, Chulalongkorn University, Biostatistics Excellence Centre, Bangkok, Thailand. <sup>8</sup>Srinagarind Hospital, Khon Kaen University, Faculty of Medicine, Khon Kaen, Thailand. <sup>9</sup>Thai AIDS Society, Bangkok, Thailand

## Oral Abstracts (continued)

Wednesday 13 November 2024

**O41: Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the National Prospective Real-World ONCOVIHAC ANRS CO24 cohort study**

Raghiatou Baldé<sup>1</sup>, Lambert Assoumou<sup>2</sup>, Christine Katlama<sup>3</sup>, Baptiste Abbar<sup>4</sup>, Pierre Delobel<sup>5</sup>, Thierry Allegre<sup>6</sup>, Armelle Lavole<sup>7</sup>, Alain Makinson<sup>8</sup>, Olivia Zaegel-Faucher<sup>9</sup>, Laurent Greillier<sup>10</sup>, Cathia Soulie<sup>11</sup>, Marianne Veyri<sup>12</sup>, Mathilde Bertheau<sup>13</sup>, Michèle Algarte Genin<sup>2</sup>, Séverine Gibowski<sup>14</sup>, Anne-Geneviève Marcelin<sup>11</sup>, Kevin Bihan<sup>15</sup>, Marine Baron<sup>16</sup>, Dominique Costagliola<sup>1</sup>, Olivier Lambotte<sup>17</sup>, Jean-Philippe Spano<sup>18</sup>

<sup>1</sup>Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Université, INSERM, Paris, France. <sup>2</sup>Institut Pierre Louis d'Epidémiologie et de Santé Publique, Sorbonne Université, INSERM, Paris, France. <sup>3</sup>AP-HP, Hôpital Pitié-Salpêtrière, Service des Maladies Infectieuses, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France. <sup>4</sup>Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Sorbonne University, Department of Medical Oncology, AP-HP, Pitié-Salpêtrière Hospital, Paris, France. <sup>5</sup>INSERM, UMR1291, Université Toulouse III Paul Sabatier, CHU de Toulouse, Service des Maladies Infectieuses et Tropicales, Toulouse, France. <sup>6</sup>Centre Hospitalier d'Aix en Provence, Department of Hematology Oncology & Internal Médecine, Aix-en-Provence, France. <sup>7</sup>AP-HP, Hôpital Tenon, Sorbonne Université, GRC#04 Theranoscan, Département de Pneumologie et Oncologie Thoracique, Paris, France. <sup>8</sup>Centre Hospitalier Universitaire de Montpellier, INSERM U1175, Département de Maladies Infectieuses, Montpellier, France. <sup>9</sup>Service d'Immuno-Hématologie Clinique, Aix-Marseille Université, APHM Sainte-Marguerite, Marseille, France. <sup>10</sup>Aix Marseille University, Assistance Publique-Hôpitaux de Marseille, Multidisciplinary Oncology and Therapeutic Innovations Department, Marseille, France. <sup>11</sup>AP-HP, Hôpital Pitié-Salpêtrière, Laboratoire de Virologie, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France. <sup>12</sup>AP-HP, Hôpital Pitié-Salpêtrière, Département d'Oncologie Médicale, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France. <sup>13</sup>INSERM-ANRS-MIE, Clinical Research, Paris, France. <sup>14</sup>INSERM-ANRS-MIE, Safety, Paris, France. <sup>15</sup>Regional Pharmacovigilance Centre, Department of Pharmacology, AP-HP, Pitié-Salpêtrière Hospital, Sorbonne University, INSERM CIC Paris-Est, AP-HP, ICAN, Paris, France. <sup>16</sup>Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Sorbonne University, Department of Medical Oncology, AP-HP, Pitié-Salpêtrière Hospital, Paris, France. <sup>17</sup>AP-HP, Hôpital Bicêtre, Université Paris-Saclay, Département d'Immunologie Clinique, Le Kremlin Bicêtre, France. <sup>18</sup>AP-HP, Hôpital Pitié-Salpêtrière, Département d'Oncologie Médicale, Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France

**O42: Depression and anxiety symptoms among people with HIV in the UK: prevalence, correlates and treatment.****Results from the Positive Voices 2022 study**

Fiona Lampe<sup>1</sup>, Colette Smith<sup>1</sup>, Annegret Pelchen-Matthews<sup>1</sup>, Adamma Aghaizu<sup>2</sup>, Meaghan Kall<sup>2</sup>, Carole Kelly<sup>2</sup>, Hannah Kitt<sup>2</sup>, Clare Humphreys<sup>2</sup>, Alex Sparrowhawk<sup>3</sup>, Elbushra Herieka<sup>4</sup>, Nicola Fearnley<sup>5</sup>, Helena King<sup>6</sup>, Fumiyo Nakagawa<sup>1</sup>, Janey Sewell<sup>1</sup>, Alison Rodger<sup>1</sup>

<sup>1</sup>University College London, Institute for Global Health, London, UK. <sup>2</sup>UK Health Security Agency, Blood Safety, Hepatitis, STI and HIV Division, London, UK. <sup>3</sup>George House Trust, HIV Advice, Support and Information, Manchester, UK. <sup>4</sup>University Hospitals Dorset NHS Foundation Trust, GUM/HIV, Bournemouth, UK. <sup>5</sup>Bradford Teaching Hospitals NHS Foundation Trust, Genitourinary Medicine, Bradford, UK. <sup>6</sup>The Open University, Department for Public Leadership and Social Enterprise, London, UK

Oral Abstracts (continued)

Wednesday 13 November 2024 (continued)

**O43: Randomised, multicentre, double-blind clinical trial designed to evaluate the safety and convenience of switching from dolutegravir/lamivudine to bicitegravir/emtricitabine/tenofovir alafenamide in people with HIV, good virological control and neuropsychiatric comorbidities: week 24 results from the GESIDA 11920 - MIND study**

Diana Corona Mata<sup>1</sup>, María José Crussells<sup>2</sup>, Maria Velasco Arribas<sup>3</sup>, Rafael Mican<sup>4</sup>, Pablo Ryan<sup>5</sup>, Marina Gallo<sup>6</sup>, Juan Tiraboschi<sup>7</sup>, Noemi Cabello Clotet<sup>8</sup>, Marta Molero<sup>9</sup>, Francisca Artigues Serra<sup>10</sup>, Alvaro Mena<sup>11</sup>, Sara de la Fuente Moral<sup>12</sup>, Javier Perez<sup>13</sup>, Mariana Diaz Almidon<sup>14</sup>, Pedro Gil<sup>15</sup>, **Ignacio Perez Valero**<sup>16</sup>

<sup>1</sup>Hospital Universitario Reina Sofia, Enfermedades Infecciosas, Cordoba, Spain. <sup>2</sup>Hospital Clínico Universitario Lozano Bless, Medicina Interna, Zaragoza, Spain. <sup>3</sup>Hospital Universitario Fundación Alcorcón, Enfermedades Infecciosas, Alcorcon, Spain. <sup>4</sup>Hospital Universitario La Paz, Medicina Interna, Madrid, Spain. <sup>5</sup>Hospital Universitario Infanta Leonor, Medicina Interna, Madrid, Spain. <sup>6</sup>Hospital Universitario Virgen Macarena, Enfermedades Infecciosas, Sevilla, Spain. <sup>7</sup>Hospital Universitari de Bellvitge, Enfermedades Infecciosas, L'Hospitalet de Llobregat, Spain. <sup>8</sup>Hospital Clínico, Enfermedades Infecciosas, Madrid, Spain. <sup>9</sup>Hospital Son Llatzer, Bonilla, Palma, Spain. <sup>10</sup>Hospital Universitario Son Espases, Medicina Interna, Palma de Mallorca, Spain. <sup>11</sup>Hospital Universitario de A Coruña, Medicina Interna, A Coruña, Spain. <sup>12</sup>Hospital Puerta de Hierro, Medicina Interna, Majadahonda, Spain. <sup>13</sup>Hospital Costa de Sol, Stachowski, Marbella, Spain. <sup>14</sup>Hospital Universitario La Paz, Bioestadística, Madrid, Spain. <sup>15</sup>Fundación SEIMC-GESIDA, Clinical Research Operations, Madrid, Spain. <sup>16</sup>Hospital Universitario Reina Sofia, IMIBIC, CIBERINFEC, Enfermedades Infecciosas, Cordoba, Spain

**O44: A phase 3 randomised study to evaluate the safety, tolerability and immunogenicity of V116, an adult-specific pneumococcal conjugate vaccine (PCV), followed by PCV15, in adults living with HIV (STRIDE-7)**

Jayani Pathirana<sup>1</sup>, **Moti Ramgopal**<sup>2</sup>, Charlotte Martin<sup>3</sup>, Johannes J Lombaard<sup>4</sup>, Carolina Chahin<sup>5</sup>, Odile Launay<sup>6</sup>, Winai Ratanasuwan<sup>7</sup>, David Greenberg<sup>8</sup>, Carlos G Grijalva<sup>9</sup>, Walter A Orenstein<sup>10</sup>, Angelika Shenkerman<sup>11</sup>, Doreen Fernsler<sup>12</sup>, Yeonil Kim<sup>13</sup>, Jianing Li<sup>13</sup>, Heather Loryn Platt<sup>14</sup>

<sup>1</sup>Merck Sharp & Dohme, Global Clinical Development, Zurich, Switzerland. <sup>2</sup>Midway Immunology and Research Center, Infectious Diseases, Fort Pierce, FL, USA. <sup>3</sup>CHU Saint-Pierre, Infectious Diseases, Brussels, Belgium. <sup>4</sup>Joshua Research, Clinical Development, Bloemfontein, South Africa. <sup>5</sup>Hospital Hernán Henríquez Aravena de Temuco-Unidad de Investigación Clínica, Specialty Care, Araucanía, Chile. <sup>6</sup>Université Paris Cité, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Inserm, F-CRIN, CIC Cochin Pasteur, Department of Vaccinology, Paris, France. <sup>7</sup>Faculty of Medicine, Siriraj Hospital, Mahidol University, Department of Preventive and Social Medicine, Bangkok, Thailand.

<sup>8</sup>Soroka University Medical Center, Pediatric Infectious Disease Unit, Beer-Sheva, Israel. <sup>9</sup>Vanderbilt University Medical Center, Health Policy, Nashville, TN, USA. <sup>10</sup>OrensteinVax, Global Health, Atlanta, GA, USA. <sup>11</sup>Merck Research Laboratories (MRL), Merck & Co., Clinical Sciences & Study Management, Rahway, NJ, USA. <sup>12</sup>Merck Research Laboratories (MRL), Merck & Co., Clinical Operations, Rahway, NJ, USA. <sup>13</sup>Merck Research Laboratories (MRL), Merck & Co., Biostatistics, Rahway, NJ, USA. <sup>14</sup>Merck Research Laboratories (MRL), Merck & Co., Global Clinical Development, Vaccines, Rahway, NJ, USA



Oral Abstracts (continued)

Wednesday 13 November 2024 (continued)

**O45: Prevalence trends of active HCV infection among people with HIV in Spain (2002-2023): nearing elimination**

Juan Berenguer<sup>1</sup>, María M Arcos<sup>2</sup>, Chiara Fanciulli<sup>1</sup>, María J Vivancos<sup>3</sup>, Pere Domingo<sup>4</sup>, Asunción Hernando<sup>5</sup>, María N Sáenz-Pérez<sup>6</sup>, Pablo Ryan<sup>7</sup>, Jordi Navarro<sup>8</sup>, Rosario Palacios<sup>9</sup>, Luis E Morano<sup>10</sup>, José A Iribarren<sup>11</sup>, Rosa Martínez<sup>12</sup>, María J Galindo<sup>13</sup>, Ignacio Santos<sup>14</sup>, Ian López-Cruz<sup>15</sup>, Antonio Rivero<sup>16</sup>, Livia Giner<sup>17</sup>, Carmen Fariñas<sup>18</sup>, Coral García<sup>19</sup>, Marta Montero<sup>20</sup>, Oscar L Ferrero<sup>21</sup>, Aroa Villoslada<sup>22</sup>, Josefa F Soler-González<sup>23</sup>, José Sanz<sup>24</sup>, Sergio Rodríguez<sup>25</sup>, Juan E Losa<sup>26</sup>, Enrique Bernal<sup>27</sup>, Sergio Veloso<sup>28</sup>, Laura Pérez-Martínez<sup>29</sup>, Fernando Mateos<sup>30</sup>, Laia Arbonés<sup>31</sup>, Raquel Franch<sup>32</sup>, Diana Corps<sup>33</sup>, Cristina Martín<sup>34</sup>, Gerardo Alonso<sup>35</sup>, Marta Clavero<sup>36</sup>, Rafael Silvariño<sup>37</sup>, Ramón Teira<sup>38</sup>, Olga Belinchon<sup>39</sup>, Marta De Miguel<sup>40</sup>, Inmaculada Jarrín<sup>41</sup>, Juan González-García<sup>2</sup>

<sup>1</sup>Hospital Gregorio Marañón, Infectious Diseases, Madrid, Spain. <sup>2</sup>Hospital La Paz, HIV Unit/Internal Medicine, Madrid, Spain. <sup>3</sup>Hospital Ramón y Cajal, Infectious Diseases, Madrid, Spain. <sup>4</sup>Hospital Santa Creu i Sant Pau, Infectious Diseases, Barcelona, Spain. <sup>5</sup>Hospital 12 Octubre, HIV Unit, Madrid, Spain. <sup>6</sup>Hospital Clínico San Carlos, Infectious Diseases/Internal Medicine, Madrid, Spain. <sup>7</sup>Hospital Infanta Leonor, Infectious Diseases/Internal Medicine, Madrid, Spain. <sup>8</sup>Hospital Vall d'Hebrón, Infectious Diseases, Barcelona, Spain. <sup>9</sup>Hospital Virgen de la Victoria, Infectious Diseases, Málaga, Spain. <sup>10</sup>Hospital Alvaro Cunqueiro, Infectious Diseases/Internal Medicine, Vigo, Spain. <sup>11</sup>Hospital Donostia, Infectious Diseases, San Sebastián, Spain. <sup>12</sup>Hospital Miguel Servet, Infectious Diseases/Internal Medicine, Zaragoza, Spain. <sup>13</sup>Hospital Clínico de Valencia, Infectious Diseases/Internal Medicine, Valencia, Spain. <sup>14</sup>Hospital de la Princesa, Infectious Diseases, Madrid, Spain. <sup>15</sup>Hospital Doctor Peset, Infectious Diseases/Internal Medicine, Valencia, Spain. <sup>16</sup>Hospital Reina Sofía de Córdoba, Infectious Diseases, Córdoba, Spain. <sup>17</sup>Hospital General de Alicante, Infectious Diseases, Alicante, Spain. <sup>18</sup>Hospital Marqués de Valdecilla, Infectious Diseases, Santander, Spain. <sup>19</sup>Hospital Virgen de las Nieves, Infectious Diseases, Granada, Spain. <sup>20</sup>Hospital La Fe, Infectious Diseases, Valencia, Spain. <sup>21</sup>Hospital de Basurto, Infectious Diseases, Bilbao, Spain. <sup>22</sup>Hospital Son Llátzer, Infectious Diseases/Internal Medicine, Palma de Mallorca, Spain. <sup>23</sup>Hospital de Cabueñes, Infectious Diseases/Internal Medicine, Gijón, Spain. <sup>24</sup>Hospital Príncipe de Asturias, Infectious Diseases/Internal Medicine, Alcalá de Henares, Spain. <sup>25</sup>Hospital de Getafe, Infectious Diseases/Internal Medicine, Getafe, Spain. <sup>26</sup>Hospital Fundación Alcorcón, Infectious Diseases, Alcorcón, Spain. <sup>27</sup>Hospital Reina Sofía de Murcia, Infectious Diseases, Murcia, Spain. <sup>28</sup>Hospital Joan XXIII, Infectious Diseases/Internal Medicine, Tarragona, Spain. <sup>29</sup>Hospital de la Rioja, Infectious Diseases/Internal Medicine, Logroño, Spain. <sup>30</sup>Hospital General de Albacete, Infectious Diseases, Albacete, Spain. <sup>31</sup>Hospital de Mataró, Infectious Diseases/Internal Medicine, Mataró, Spain. <sup>32</sup>Hospital Virgen de la Cinta, Infectious Diseases/Internal Medicine, Tortosa, Spain. <sup>33</sup>Hospital de Torrejón, Infectious Diseases/Internal Medicine, Torrejón de Ardoz, Spain. <sup>34</sup>Hospital Virgen de la Concha, Infectious Diseases/Internal Medicine, Zamora, Spain. <sup>35</sup>Hospital Rafael Méndez, Infectious Diseases/Internal Medicine, Lorca, Spain. <sup>36</sup>Hospital Infanta Elena, Infectious Diseases/Internal Medicine, Valdemoro, Spain. <sup>37</sup>Hospital San Eloy, Infectious Diseases/Internal Medicine, Baracaldo, Spain. <sup>38</sup>Hospital de Sierrallana, Infectious Diseases/Internal Medicine, Torrelavega, Spain. <sup>39</sup>Hospital Virgen de la Luz, Infectious Diseases/Internal Medicine, Cuenca, Spain. <sup>40</sup>Fundación SEIMC/GESIDA, Clinical Investigation, Madrid, Spain. <sup>41</sup>Instituto de Salud Carlos III, Centro Nacional de Epidemiología, Madrid, Spain

## Oral Abstracts (continued)

Wednesday 13 November 2024 (continued)

**O46A: Long-term outcomes following liver transplantation (LT) in patients with HIV (PWH): a retrospective single-centre case-control study**

Sheila Blanco<sup>1</sup>, Lucia Serrano<sup>2</sup>, Pablo Ruiz<sup>3</sup>, Daniela Malano<sup>1</sup>, Montserrat Laguno<sup>4</sup>, Alejandro Forner<sup>5</sup>, Christian Manzardo<sup>1</sup>, Gonzalo Crespo<sup>5</sup>, Hugo Lopez<sup>6</sup>, Anna Lligoña<sup>6</sup>, Josep Fuster<sup>7</sup>, Constantino Fondevila<sup>7</sup>, Juan C Garcia-Valdecasas<sup>7</sup>, Montserrat Tuset<sup>8</sup>, Asuncion Moreno<sup>1</sup>, Antonio Rimola<sup>5</sup>, Jose M Miro<sup>4</sup>

<sup>1</sup>Hospital Clinic-IDIBAPS-University of Barcelona, Infectious Diseases Service - HIV/AIDS Unit, Barcelona, Spain.

<sup>2</sup>Fundación SEIMC-GESIDA, Statistics Department, Madrid, Spain. <sup>3</sup>Hospital Clinic-IDIBAPS-University of Barcelona, Hepatology Service - Liver Transplant Unit, Barcelona, Spain. <sup>4</sup>Hospital Clinic-IDIBAPS-University of Barcelona-CIBERINFEC, Infectious Diseases Service - HIV/AIDS Unit, Barcelona, Spain. <sup>5</sup>Hospital Clinic-IDIBAPS-University of Barcelona-CIBEREHD, Hepatology Service - Liver Transplant Unit, Barcelona, Spain. <sup>6</sup>Hospital Clinic-IDIBAPS-University of Barcelona, Psychiatry Service, Barcelona, Spain. <sup>7</sup>Hospital Clinic-IDIBAPS-University of Barcelona, Hepatopancreatobiliary Surgery and Transplantation, General and Digestive Surgery Service, Barcelona, Spain.

<sup>8</sup>Hospital Clinic-IDIBAPS-University of Barcelona, Pharmacy Department, Barcelona, Spain

**O46B: HIV-positive donor to positive recipient kidney transplantation: a nationwide survey**

Nerea L Amondarain<sup>1</sup>, Lucia Serrano<sup>2</sup>, David Paredes<sup>3</sup>, Beatriz Mahillo<sup>4</sup>, Gloria de la Rosa<sup>4</sup>, Daniela Malano<sup>1</sup>, Christian Manzardo<sup>1</sup>, Frederic Cofan<sup>5</sup>, Angela Gonzalez<sup>5</sup>, David Cucchiari<sup>5</sup>, Mireia Musquera<sup>5</sup>, Elisa de Lazzari<sup>1</sup>, Antonio Rimola<sup>6</sup>, Asuncion Moreno<sup>1</sup>, **Jose M. Miro**<sup>1</sup>

<sup>1</sup>Hospital Clinic-Institut D'investigacions Biomèdiques August Pi I Sunyer (IDIBAPS)-University of Barcelona, Infectious Diseases Service - HIV/AIDS Unit, Barcelona, Spain. <sup>2</sup>Fundación Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC)-Grupo de Estudio del Sida (GeSIDA), Statistical Department, Madrid, Spain.

<sup>3</sup>Hospital Clinic-IDIBAPS-University of Barcelona, Transplant Coordination Department, Barcelona, Spain.

<sup>4</sup>Organización Nacional de Trasplantes (ONT), Transplant Coordination Department, Madrid, Spain. <sup>5</sup>Hospital Clinic-IDIBAPS-University of Barcelona, Department of Nephrology and Urology, Barcelona, Spain. <sup>6</sup>Hospital Clinic-IDIBAPS-University of Barcelona, Department of Hepatology and Liver Transplantation, Barcelona, Spain

**O47: Differences in oral PrEP use patterns and intention to use long-acting regimens among MSM between formal and informal PrEP provision pathways in 20 European countries: a latent class analysis**

**Haoyi Wang**<sup>1</sup>, Alejandro Adriaque Lozano<sup>1</sup>, Hanne Zimmermann<sup>1</sup>, Johann Kolstee<sup>1</sup>, Melanie Schroeder<sup>2</sup>, Ama Appiah<sup>3</sup>, Ana Milinkovic<sup>4</sup>, Supriya Sarkar<sup>2</sup>, Kai Jonas<sup>1</sup>

<sup>1</sup>Maastricht University, Applied Social Psychology, Maastricht, Netherlands. <sup>2</sup>ViiV Healthcare, Global Health Outcomes, Brentford, UK. <sup>3</sup>ViiV Healthcare, Patient Engagement, Brentford, UK. <sup>4</sup>ViiV Healthcare & Chelsea and Westminster Hospital, Global Medical, Brentford, London, UK

**O48: Persistence in use of twice-yearly lenacapavir versus daily oral PrEP in the PURPOSE 1 phase 3 trial**

**Linda-Gail Bekker**<sup>1</sup>, Noah Kiwanuka<sup>2</sup>, Pearl Selepe<sup>3</sup>, Amy Ward<sup>4</sup>, Ramin Ebrahimi<sup>5</sup>, Yang Zhao<sup>5</sup>, Christoph Carter<sup>5</sup>, Alexander Kintu<sup>5</sup>, Jenna Yager<sup>5</sup>, Moupali Das<sup>5</sup>, Quarraisha Abdool Karim<sup>6</sup>, on behalf of the PURPOSE 1 Study Group

<sup>1</sup>University of Cape Town, The Desmond Tutu HIV Centre, Cape Town, South Africa. <sup>2</sup>Makerere University School of Public Health, Department of Epidemiology and Biostatistics, Kampala, Uganda. <sup>3</sup>The Aurum Institute – Klerksdorp Clinical Research Site, Clinical Research Division, Klerksdorp, South Africa. <sup>4</sup>University of Cape Town, Department of Medicine, Vuka Research Clinic, Cape Town, South Africa. <sup>5</sup>Gilead Sciences Inc., Foster City, CA, USA. <sup>6</sup>Department of Epidemiology and Prevention, Centre for the AIDS Programme of Research in South Africa, Durban, South Africa, and Department of Epidemiology, Mailman School of Public Health, New York, NY, USA

Oral Abstracts (continued)

Wednesday 13 November 2024 (continued)

**O49: Twice-yearly lenacapavir PrEP in cisgender gay men, transgender women and men, and gender-diverse people (PURPOSE 2)**

Colleen F Kelley<sup>1</sup>, Maribel Acevedo-Quiñones<sup>2</sup>, Allison L Agwu<sup>3</sup>, Anchalee Avihingsanon<sup>4</sup>, Paul Benson<sup>5</sup>, Jill Blumenthal<sup>6</sup>, Cynthia Brinson<sup>7</sup>, Carlos Brites<sup>8</sup>, Pedro Cahn<sup>9</sup>, Valeria D Cantos<sup>10</sup>, Jesse Clark<sup>11</sup>, Meredith Clement<sup>12</sup>, Cathy Creticos<sup>13</sup>, Gordon Crofoot<sup>14</sup>, Ricardo S Diaz<sup>15</sup>, Susanne Doblecki-Lewis<sup>16</sup>, Jorge A Gallardo-Cartagena<sup>17</sup>, Aditya Gaur<sup>18</sup>, Beatriz Grinsztejn<sup>19</sup>, Juan Carlos Hinojosa<sup>20</sup>, Theo Hodge<sup>21</sup>, Richard Kaplan<sup>22</sup>, Marcus Lacerda<sup>23</sup>, Anthony LaMarca<sup>24</sup>, Marcelo H Losso<sup>25</sup>, Jose Valdez Madruga<sup>26</sup>, Kenneth H Mayer<sup>27</sup>, Anthony Mills<sup>28</sup>, Karam Mounzer<sup>29</sup>, Nkosiphile Ndlovu<sup>30</sup>, Richard M Novak<sup>31</sup>, Alma Perez Rios<sup>32</sup>, Nittaya Phanuphak<sup>33</sup>, Moti Ramgopal<sup>34</sup>, Peter J Ruane<sup>35</sup>, Breno Santos<sup>36</sup>, Patric Schine<sup>37</sup>, Tanya Schreibman<sup>38</sup>, LaShonda Y Spencer<sup>39</sup>, Olivia T Van Gerwen<sup>40</sup>, Ricardo Vasconcelos<sup>41</sup>, Jose Gabriel Vasquez<sup>42</sup>, Zwelethu Zwane<sup>43</sup>, Stephanie Cox<sup>44</sup>, Chris Deaton<sup>45</sup>, Ramin Ebrahimi<sup>44</sup>, Pamela Wong<sup>44</sup>, Renu Singh<sup>44</sup>, Lillian B Brown<sup>44</sup>, Christoph C Carter<sup>44</sup>, Moupani Das<sup>44</sup>, Jared M Baeten<sup>44</sup>, **Onyema Ogbuagu**<sup>46</sup>, on behalf of the PURPOSE 2 Study Group

<sup>1</sup>Decatur, GA and Grady Health System, Hope Clinic of Emory University School of Medicine, Atlanta, GA, USA. <sup>2</sup>Centro Ararat, San Juan, Puerto Rico. <sup>3</sup>The Johns Hopkins University School of Medicine, Divisions of Pediatric and Adult Infectious Diseases, Baltimore, MD, USA. <sup>4</sup>Thai Red Cross AIDS Research Centre and Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University, The HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand. <sup>5</sup>Be Well Medical Center, Berkley, MI, USA. <sup>6</sup>University of California San Diego, Department of Medicine, San Diego, CA, USA. <sup>7</sup>Central Texas Clinical Research, Austin, TX, USA. <sup>8</sup>Complexo Hospitalar Universitário Professor Edgard Santos, Salvador, Brazil. <sup>9</sup>Fundación Huésped, Buenos Aires, Argentina. <sup>10</sup>Emory University - Ponce de Leon Center Clinical Research Site, HIV/AIDS Clinical Trials Unit, Division of Infectious Diseases, Atlanta, GA, USA. <sup>11</sup>University of California, Department of Medicine, Los Angeles, CA, USA. <sup>12</sup>Louisiana State University Health Sciences Center - New Orleans, Department of Infectious Diseases, New Orleans, LA, USA. <sup>13</sup>Howard Brown Health, Chicago, IL, USA. <sup>14</sup>Crofoot MD Clinic and Research Center, Houston, TX, USA. <sup>15</sup>Universidade Federal de São Paulo, São Paulo, Brazil. <sup>16</sup>University of Miami Miller School of Medicine, Division of Infectious Diseases, Miami, FL, USA. <sup>17</sup>Universidad Nacional Mayor de San Marcos, Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales, Lima, Peru. <sup>18</sup>St Jude Children's Research Hospital, Department of Infectious Diseases, Memphis, TN, USA. <sup>19</sup>Fundação Oswaldo Cruz - Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil. <sup>20</sup>Asociación Civil Selva Amazónica, Iquitos, Peru. <sup>21</sup>Washington Health Institute, Washington, DC, USA. <sup>22</sup>Desmond Tutu Health Foundation, Cape Town, South Africa. <sup>23</sup>Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Brazil. <sup>24</sup>Therafirst Medical Center, Fort, FL, USA. <sup>25</sup>Hospital General de Agudos José María Ramos Mejía, Buenos Aires, Argentina. <sup>26</sup>Centro de Referência e Treinamento DST/AIDS-SP, São Paulo, Brazil. <sup>27</sup>Harvard Medical School, The Fenway Institute, Fenway Health and Department of Medicine, Boston, MA, USA. <sup>28</sup>Mills Clinical Research, West Hollywood, CA, USA. <sup>29</sup>Jonathan Lax Treatment Center, Philadelphia FIGHT Community Health Centers, Philadelphia, PA, USA. <sup>30</sup>University of the Witwatersrand, Wits RHI, Faculty of Health Sciences, School of Public Health, Johannesburg, South Africa. <sup>31</sup>University of Illinois Health Sciences, Division of Infectious Diseases, Chicago, IL, USA. <sup>32</sup>Centro de Investigación Farmaceutica Especializada de Occidente SC, Guadalajara, Mexico. <sup>33</sup>Pribta Tangerine Clinic, Institute of HIV Research and Innovation, Bangkok, Thailand. <sup>34</sup>Midway Immunology and Research Center, Fort Pierce, FL, USA. <sup>35</sup>Ruane Clinical Research, Los Angeles, CA, USA. <sup>36</sup>Hospital Nossa Senhora da Conceição, Infectious Diseases Service, Port Alegre, Brazil. <sup>37</sup>Bios Clinical Research, LLC, Palm Springs, CA, USA. <sup>38</sup>CAN Community Health, Sarasota, FL, USA. <sup>39</sup>Charles R. Drew University, Drew Center for AIDS Research, Education, and Services, Los Angeles, CA, USA. <sup>40</sup>University of Alabama at Birmingham, Department of Medicine, Division of Infectious Diseases, Birmingham, AL, USA. <sup>41</sup>Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. <sup>42</sup>Via Libre, Lima, Peru. <sup>43</sup>The Aurum Institute – Pretoria Clinical Research Site, Pretoria, South Africa. <sup>44</sup>Gilead Sciences, Foster City, CA, USA. <sup>45</sup>Gilead Sciences, Cambridge, UK. <sup>46</sup>Yale School of Medicine, Section of Infectious Diseases, New Haven, CT, USA